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Experimental and clinical data suggest that pro-angiogenic, pro-inflammatory and
mitogenic cytokine leptin can be implicated in ocular neovascularization and other eye
pathologies. At least in part, leptin action appears to be mediated through functional
interplay with vascular endothelial growth factor (VEGF). VEGF is a potent regulator
of neoangiogenesis and vascular leakage with a proven role in conditions such as
proliferative diabetic retinopathy, age-related macular degeneration and diabetic macular
edema. Accordingly, drugs targeting VEGF are becoming mainstream treatments for
these diseases. The crosstalk between leptin and VEGF has been noted in different
tissues, but its involvement in the development of eye pathologies is unclear. Leptin
is coexpressed with VEGF during ocular neovascularization and can potentiate VEGF
synthesis and angiogenic function. However, whether or not VEGF regulates leptin
expression or signaling has never been studied. Consequently, we addressed this
aspect of leptin/VEGF crosstalk in ocular models, focusing on therapeutic exploration
of underlying mechanisms. Here we show, for the first time, that in retinal (RF/6A)
and corneal (BCE) endothelial cells, VEGF (100 ng/mL, 24 h) stimulated leptin mRNA
synthesis by 70 and 30%, respectively, and protein expression by 56 and 28%,
respectively. In parallel, VEGF induced RF/6A and BCE cell growth by 33 and 20%,
respectively. In addition, VEGF upregulated chemotaxis and chemokinesis in retinal cells
by ∼40%. VEGF-dependent proliferation and migration were significantly reduced in the
presence of the leptin receptor antagonist, Allo-aca, at 100–250 nmol/L concentrations.
Furthermore, Allo-aca suppressed VEGF-dependent long-term (24 h), but not acute
(15min) stimulation of the Akt and ERK1/2 signaling pathways. The efficacy of Allo-aca
was validated in the rat laser-induced choroidal neovascularization model where the
compound (5µg/eye) significantly reduced pathological vascularization with the efficacy
similar to that of a standard treatment (anti-VEGF antibody, 1µg/eye). Cumulatively,
our results suggest that chronic exposure to VEGF upregulates leptin expression and
function. As leptin can in turn activate VEGF, the increased abundance of both cytokines
could amplify pro-angiogenic and pro-inflammatory environement in the eye. Thus,
combined therapies targeting ObR and VEGF should be considered in the treatment
of ocular diseases.
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INTRODUCTION
Leptin, a pluripotentcytokine produced in the adipose tissue, has
been first discovered as a hormone regulating energy balance
and appetite via hypothalamic signals (Wauters et al., 2000;
Scolaro et al., 2010). In addition to its metabolic functions in
the CNS, leptin is known to regulate multiple physiological and
pathological processes, e.g., immune responses, hematopoiesis,
bone remodeling, cardiovascular function, normal and neoplastic
cell growth (Surmacz, 2013; Surmacz and Otvos, 2015; Upadhyay
et al., 2015; Meek and Morton, 2016; Naylor and Petri, 2016).
Although adipocytes are the main source of leptin, the hormone
can be produced by different types of cells and in different organs
(Scolaro et al., 2010; Sweeney, 2010; Surmacz, 2013).
This study focuses on the angiogenic function of leptin
and its involvement in ocular neovascularization. The leptin
receptor (ObR) is expressed in vascular endothelial cells and
studies in vitro demonstrated that leptin can induce angiogenic
differentiation as well as proliferation and migration of
endothelial cells, including cells of ophthalmic origin (Bouloumié
et al., 1998; Sierra-Honigmann et al., 1998; Cao et al., 2001;
Park et al., 2001; Anagnostoulis et al., 2008; Ferla et al., 2011;
Garonna et al., 2011; Scolaro et al., 2013; Parrino et al., 2014;
Adya et al., 2015). In mouse models, transgenic overexpression
of the leptin gene (ob) potentiated ischemia-induced retinal
neovascularization, while leptin deficiency due to ob inactivation,
significantly reduced ocular angiogenesis, proving again the role
of this cytokine in neovascularization (Suganami et al., 2004).
Similarly, leptin was not able to induce neovascularization in
corneas of fa/fa Zucker rats that lack functional ObR, underlying
the importance of leptin signaling in this process (Sierra-
Honigmann et al., 1998).
We have recently demonstrated that leptin is a potent
mitogenic and angiogenic factor in retinal and corneal
endothelial cells (Scolaro et al., 2013; Parrino et al., 2014).
We have described that these leptin functions are associated with
the modulation of the activity or expression of several signaling
molecules involved in proliferation, inflammatory activity
and angiogenesis, including the transcription factor STAT3,
common kinases Ras, ERK1/2 and Akt, pro-inflammatory
mediators and regulators COX2 and NF-κB. Furthermore, we
have found that leptin can upregulate its own mRNA and protein
expression in retinal and corneal cells, suggesting the existence
of leptin autocrine circuits in the eye. We have validated leptin
involvement in the above processes using a selective and highly
efficacious ObR antagonist Allo-aca, a leptin peptidomimetic
that blocks ObR activation and biological activity at low-mid
nmol//L concentrations in vitro in different cell types (Scolaro
et al., 2013; Parrino et al., 2014).
The mechanisms of leptin expression in the eye are still
under investigation. Previous studies have shown that eye
injury, ischemic or hyperglycemic conditions can increase leptin
expression (Suganami et al., 2004; Sun et al., 2010, 2011). We
have recently reported that hyperglycemia can induce leptin
mRNA and protein expression in retinal endothelial cells and
that this process is associated with increased angiogenesis, cell
growth and migration. These effects can be partially reversed
by ObR antagonist Allo-aca, implicating leptin signaling in the
pathological processes caused by high glucose levels (Parrino
et al., 2014).
Adding to the bulk of experimental data, some recent clinical
reports suggest that leptin can be involved in eye pathologies.
For instance, in patients with proliferative diabetic retinopathy
(PDR) or retinal detachment (RD), intravitreous leptin levels
were significantly elevated compared with that in patients with
other ocular diseases (Gariano et al., 2000; Kovacs et al., 2015).
In addition, the study suggested that locally produced leptin, not
simply leptin derived from circulation, could be involved in the
pathogenesis of PDR and RD (Gariano et al., 2000). Similarly,
a small study confirmed higher vitreous leptin levels in PDR
relative to other retinopathies (Maberley et al., 2006). Whether
leptin is causally related to the progression of DR is still under
investigation.
An important aspect of leptin’s role in the regulation
of key processes implicated in eye diseases is its functional
connection with vascular endothelial growth factor (VEGF),
a major regulator of neoangiogenesis and vascular leakage
with a proven role in ocular pathologies such as PDR, age-
related macular degeneration (AMD) and diabetic macular
edema (DME) (Miller, 2016). Notably, experimental evidence
suggests that leptin can induce and amplify VEGF expression
and signaling. For instance, in tetrandrine-induced corneal
neovascularization model, leptin is found coexpressed with
VEGF (Sun et al., 2011). In ischemia-induced neovascularization,
leptin can potentiate vessel formation through induction of
VEGF expression (Suganami et al., 2004). In endothelial
HUVEC cells, leptin stimulats angiogenesis simultaneously with
upregulation of VEGF expression (Bouloumié et al., 1998; Sierra-
Honigmann et al., 1998). Furthermore, in HUVEC cells, leptin-
mediated angiogenesis and intracellular signaling through the
p38 MAPK/Akt/COX-2 pathway is partially reduced with a
VEGFR inhibitor, implicating this receptor in leptin response
(Garonna et al., 2011). In syngeneic mammary cancer models,
the inhibition of leptin signaling significantly reduces the levels
of VEGF and its receptor VEGFR2 (Newman and Gonzalez-
Perez, 2014). The codependence of VEGF and leptin expression
has been also noted in ob/ob mice where lack of functional
leptin is associated with increased circulating concentrations of
VEGF-A and leptin replacement normalizes VEGF-A levels in
this model. In addition, leptin regulation of VEGF-A expression
has been demonstrated in obese subjects before and after weight
loss (Gómez-Ambrosi et al., 2010).
However, whether or not leptin/VEGF crosstalk is a bilateral
relationship, i.e., if VEGF can influence leptin expression and
function, has never been studied. Consequently, this aspect
of leptin/VEGF crosstalk and the potential of therapeutic
exploration of the underlying mechanism is the subject of the
present paper.
At present, several biologic drugs targeting VEGF and/or its
receptor have been approved for ophthalmology use (van der Giet
et al., 2015; Miller, 2016). However, new treatments, perhaps with
broader therapeutic spectrum, are needed to decrease adverse
effects and/or complement anti-VEGF drugs (Tang and Kern,
2011; Truong et al., 2011; Chen et al., 2013; van der Giet et al.,
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2015). In this context, targeting leptin, a known pro-angiogenic
and pro-inflammatory factor whose function is intimately related
to VEGF, could prove provide an attractive targeted therapy for
pathological neovascularization in the eye (Cheung et al., 2010).
MATERIALS AND METHODS
Reagents
The ObR antagonist, Allo-aca, a short leptin-based
peptidomimetic (H-alloThr-Glu-Nva-Val-Ala-Leu-Ser-Arg-
Aca-NH2) was used to inhibit ObR signaling and function. The
process of Allo-aca design, development and efficacy in vitro,
including the ophthalmic models, and in vivo has been reported
by us before (Otvos et al., 2011a,b; Scolaro et al., 2013; Parrino
et al., 2014). VEGF (human recombinant, VEGF 165) was
purchased from Gibco Life Technologies (Grand Island, NY).
Cell Lines and Growth Conditions
The cellular assays were performed using monkey endothelial
retinal cells (RF/6A) and bovine endothelial corneal cells (BCE).
The cells were purchased and cultured as recommended by the
supplier (American Type Culture Collection, Rockville, MD,
USA) and describe by us in detail previously (Scolaro et al.,
2013). Cell culture reagents and media were purchased from
Cellgro (Herndon, VA, USA). Before treatments, the cells were
synchronized in serum-free medium (SFM) containing 10µM
FeSO4 0.5% bovine serum albumin, 1% FBS, 1% Pen/Strep. We
have shown before that RF/6A and BCE ocular endothelial cell
lines express ObR and respond to leptin with the activation of
various biological functions, i.e., growth, signaling, angiogenesis,
migration (Scolaro et al., 2013; Parrino et al., 2014).
Proliferation Assay
The cells (5–7th passage) were plated in 24-well plates at
concentrations 5–8 × 104 and 1–1.5 × 105 cells/well for RF/6A
and BCE cells, respectively. At semi-confluence, the cells were
shifted to SFM for 24 h and then treated with 50–250 ng/mL
of VEGF for 24 h, without 100–250 nmol/L Allo-aca. All assays
were done in triplicate and repeated 3 times. Cell numbers
were determined by direct counting as describe by us previously
(Scolaro et al., 2013). The percentage decrease/increase in
cell number vs. control SFM was calculated and expressed as
mean± standard deviation (SD).
Quantitative Real Time PCR (qRT-PCR)
Leptin mRNA was detected by qRT-PCR as described in detail
previously (Scolaro et al., 2013). Briefly, RF/6A and BCE cells
at semi-confluence were placed in SFM for 24 h, pretreated or
not with 250 nmol/L Allo-aca for 1 h, and then treated with 100
ng/mL VEGF for 6 and 24 h. RNA was isolated from cultures
using Trizol Reagent (Life Technologies, Grand Island, NY) and
4µg of RNA was reverse transcribed using the High-Capacity
cDNA Kit (Life Technologies). The RT products were used to
amplify leptin sequences using TaqMan probes Bt03211909_m1
for bovine leptin (Gene ID: 280836) and Rh02788316_m1 for
monkey leptin (Gene ID: 698728) (Life Technologies). For
normalization, parallel reactions were run on each sample for
β-actin using a TaqMan probe (Life Technologies). The levels of
leptin mRNA relative to β-actin mRNA were determined using a
comparative CT method (Life Technologies). All reactions were
done in triplicate and an average CT value (±SD) for all RNAs
was calculated. The individual experiments were repeated at least
3 times.
Wound-Healing (Scratch) Assay
Directional cell migration in vitro was assessed using a wound-
healing assay. Linear scratches (3 per plate) were produced in
100% confluent cultures of RF/6A cells using a 200µL tip. The
cultures were then shifted to SFM, SFM containing 100 ng/mL
VEGF, or SFMwith 100 ng/mL VEGF plus 100–250 nmol/L Allo-
aca for 24 h. Wound dimensions (at least 6 fields/experimental
condition) were recorded with Olympus 1 × 81 phase-contrast
microscope at 2.0xmagnification and images were acquired using
Metamorph 7.5 program. The scratch areas were quantified using
the Adobe Acrobat Pro program and the areas expressed in
arbitrary units (AU).
Transwell Migration Assays
The effects of VEGF on chemotactic properties of RF/6A cells
were studied using Transwell inserts (8.0µmpore size) (Corning,
Tewksbury, MA). The cells (5–6th passage) were plated at
concentrations 5× 104 cells/well and allowed to migrate through
the membrane for 24 h. Then, non-migrated cells in the upper
chamber were removed and the cells that migrated across the
membranes were stained with Giemsa for 20min and counted.
To test chemotactic effects of VEGF on RF/6A cells, 100 ng/mL
VEGF was added to the lower chamber only. The involvement
of VEGF-dependent chemokinesis was assessed using 100 or
250 nmol/L Allo-aca. Each migration assay was done in triplicate
and repeated at least 3 times and the mean number of migrated
cells± SD was determined.
Immunofluorescence
Leptin protein was detected in RF/6A and BCE cells by
immunofluorescence (IF), as described by us before (Bartella
et al., 2008; Cascio et al., 2008; Scolaro et al., 2013). In short,
1 × 105 cells were plated on glass coverslips in normal growth
medium. After 24 h, the cells were synchronized in SFM for
24 h and then treated either with 100 ng/mL VEGF in the
absence or presence of 100 or 250 nmol/L Allo-aca for 24
h. Next, the cells were washed with PBS, fixed in methanol,
and permeabilized in 0.2 Triton X-100%. Leptin expression was
detected using pAb A-20 (1:25 dilution; 2 h) and goat anti-
rabbit IgG-FITC (1:1000 plus 1.5% blocking goat serum; 1 h).
In control experiments, primary Abs were replaced by non-
immune serum. To visualize cell nuclei, the coverslips were
mounted with UltraCruz Mounting Medium containing DAPI
(5µg/mL of 4′,6-diamidino-2-phenylindole). The expression of
leptin was detected using Olympus 1 × 81 phase-contrast
microscope at 3.2xmagnification. The percentage of positive cells
was determined in 10 visual fields. All reagents were purchased
from Santa Cruz Biotechnology (Dallas, TX).
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Intracellular Signaling
The effects of Allo-aca on VEGF-induced signaling in RF/6A
cells were tested by Western immunoblotting (WB). In brief,
cells were synchronized in SFM for 24 h and then treated with
100 ng/mL VEGF in the presence or absence of 250 nmol/L
Allo-aca for 24 h or were left untreated. Next, total cellular
proteins were obtained and the expression and activation of
signaling molecules was evaluated with specific antibodies (Abs)
as described previously (Scolaro et al., 2013). The following
primary Abs from Cell Signaling Technology (Danvers, MA)
were used: phospho-Akt, Akt Ser473 pAb, 1:500; total Akt,
Akt pAb, 1:1000; phospho-STAT3, STAT3 Tyr705, D3A7 mAb,
1:500; total STAT3, STAT3 79D7 mAb, 1:500; phospho-ERK1/2,
p44/42 mitogen-activated protein kinase (MAPK; ERK1/2) pAb
Thr202/Tyr204, 1:1000; total ERK1/2, p44/42 MAPK pAb,
1:1000. The experiments were repeated at least 3 times.
Densitometry Evaluation of Protein
Expression
The intensity of bands corresponding to studied proteins
was measured in all WB as described before using Image J
program (National Institutes of Health; Scolaro et al., 2013).
The modifications in protein expression/phosphorylation were
evaluated as decrease/increase vs. SFM (% ± SD), differences
with p ≤ 0.05 were considered significant.
Laser-Induced Choroidal
Neovascularization (CNV) Assays
All animal experiments conformed to the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. A 22-day
study was conducted in female 6 week old Brown Norway rats
to determine the antiangiogenic/vascular disrupting effects of the
leptin receptor antagonist, Allo-aca, in a laser induced model
of CNV. The animals were divided into 3 separate treatment
groups of 6 animals per group. On day 1, laser treatments
were performed on all groups using a 520 nmol/L thermal laser
to generate a total of three lesions per eye. On day 3, group
1 received bilateral intravitreal (ivt) injections of the vehicle,
group 2 (positive control) received bilateral ivt injections of an
anti-VEGF antibody (R&D Systems, AF564) at 1µg/eye, and
group 3 (test) received bilateral intravitreal injections of Allo-
aca at 5µg/eye. Intravitreal administration of Allo-aca was well
tolerated by the rats and no adverse events were observed. On
Day 22 (3-weeks post-laser treatment), fluorescein angiography
was performed and lesion size area was determined following
hand tracing of the lesions using image analysis software ImageJ.
The experiments were performed under animal protocol 11-
156-H approved by the IACUC committee of the University of
Oklahoma Health Sciences Center.
Statistical Analysis
The results of in vitro and CNV experiments were analyzed by
a two-tailed distribution paired Student’s t-test; p ≤ 0.05 were
considered statistically significant.
RESULTS
VEGF Induces Leptin mRNA and Protein
Expression in Ocular Endothelial Cells.
Allo-aca Reduces These Effects
The effects of VEGF on leptin expression were assessed in
ocular endothelial cell models RF/6A and BCE. In both cell
lines, VEGF was tested at 100 ng/mL concentrations for 24 h.
The treatment significantly induced leptin mRNA expression in
both cell lines (Table 1). VEGF upregulation of leptin mRNA
was more pronounced in RF/6A cells (∼1.7-fold) vs. BCE cells
(∼1.3-fold).
Similarly, exposure to VEGF for 24 h significantly increased
the number of cells with well detectable expression of the leptin
protein. In both cell lines, the level of leptin-positive cells under
SFM conditions was below 1%, while upon VEGF treatment,
56± 5% of RF/6A cells and 28± 3% of BCE cells displayed leptin
expression (Figure 1). The upregulation of leptin expression in
both cell lines by VEGF was statistically significant.
As leptin is known to stimulate its own expression, we probed
if the inhibition of leptin signaling can decrease the above VEGF
effects. To this end, we employed a peptide antagonist of the
leptin receptor, Allo-aca, that has been shown to block leptin
signaling and action in numerous in vitro and in vivo models
(Otvos et al., 2011a,b; Scolaro et al., 2013; Parrino et al., 2014).
In the present work, Allo-aca at 250 nmol/L reduced VEGF-
dependent leptin mRNA expression in both cell lines below base
levels (Table 1). Similarly, addition of Allo-aca at 250 nmol/L to
VEGF treatment reduced the number of leptin-positive cells in
RF/6A and BCE cultures by 75 ± 4 and 80 ± 5%, respectively
(Figure 1).
ObR Antagonist Allo-aca Inhibits VEGF
Mitogenic Effects
In addition to strong pro-angiogenic activities, VEGF is known
to induce mitogenesis in different endothelial cell models (Lu
et al., 2010). Similarly, leptin can increase cell growth in BCE
and RF/6A cells, as previously demonstrated by us (Scolaro
et al., 2013). Because VEGF increased leptin expression in
these cell models, we speculated that at least part of VEGF
mitogenic action is mediated through the leptin/ObR axis. To
test this hypothesis, we examined if VEGF-mediated growth
could be reduced in the presence of the ObR antagonist,
Allo-aca.
TABLE 1 | VEGF induces leptin mRNA expression in BCE and RF6A cells.
BCE Leptin mRNA levels
(fold ± SD over SFM)
RF/6A Leptin mRNA Expression
(fold ± SD over SFM)
SFM 1.0 1.0
VEGF 1.3 ± 0.2* 1.7 ± 0.1*
VEGF + Allo-aca 0.9 ± 0.1# 0.6 ± 0.2#
Leptin mRNA levels in cells treated with 100 ng/mL VEGF for 24 h were measured by QRT-
PCR as described in Materials and Methods. Statistically significant differences (p ≤ 0.05)
vs. SFM are marked with * and vs. VEGF with #.
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First, we found that VEGF at 50–250 ng/mL induced
proliferation in BCE and RF/6A cells. In both cell lines, the
best growth response was observed with VEGF used at 100
ng/mL (Table 2). In the presence of Allo-aca at 100 or 250
nmol/L, VEGF-induced proliferation was either reduced to base
or below base levels (Table 2), suggesting that leptin pathways are
implicated in VEGF response.
Allo-aca Inhibits VEGF-Induced
Chemotaxis and Chemokinesis in RF/6A
Retinal Endothelial Cells
VEGF as well as leptin are well recognized as regulators of
chemotaxis and chemokinesis–processes that are intimately
involved in angiogenic differentiation. To assess if VEGF
effects on chemotaxis and chemokinesis are mediated
indirectly through ObR, we used RF/6A cells, characterized
by robust migratory abilities in vitro. The migration of
RF/6A cells was measured in wound-healing and Transwell
assays.
In wound-healing assay, basal cell migration was observed
even in SFM at 24 h after cell plating, likely due to the activity of
autocrine pro-migratory factors (e.g., leptin) produced by RF/6A
cells (Scolaro et al., 2013).
Addition of VEGF at 100 ng/mL further stimulated cell
motility, reflected by significantly reduced (∼40%) scratch
area compared with that under untreated SFM conditions
(p ≤ 0.05) (Figure 2). The effects of VEGF were totally
abolished (p ≤ 0.05) in the presence of 250 nmol/L Allo-aca
(Figure 2).
In the Transwell assay, VEGF at 100 mg/mL induced
directional migration of ∼37% of RF/6A cells. Addition of Allo-
aca at 100 nmol/L partially (∼46%) reduced VEGF effects, while
Allo-aca at 250 nmol/L blocked VEGF-directed migration by
∼92% (Table 3).
TABLE 2 | VEGF induces cell growth in BCE and RF/6A cells.
Treatment BCE Growth response
(% ± SD over SFM)
RF/6A Growth response
(% ± SD over SFM)
VEGF 50 9.0 ± 0.9* 7.1 ± 0.2*
VEGF 100 20.4 ± 1.7* 33.1 ± 1.9*
VEGF 250 16.2 ± 1.8* 29.3 ± 1.9*
VEGF 100 + Allo-aca 100 −4.0 ± 0.0* 4.0 ± 0.1*
VEGF 100 + Allo-aca 250 −18.0 ± 1.2* −4.1 ± 1.3
Allo-aca inhibits VEGF mitogenic effects. Proliferation assays were carried out as
described in Materials and Methods. Increase of cell number (%) over that in SFM is
shown. VEGF was used at 50–250 ng/mL; Allo-aca was used at 100 and 250 nmol/L.
Statistically significant differences (p ≤ 0.05) vs. SFM are marked with asterisk.
FIGURE 1 | VEGF induces leptin protein expression in BCE and RF6A cells. Cells were synchronized in SFM and stimulated with 100 ng/mL VEGF for 24 h in
the presence or absence of 250 nmol/L Allo-aca (Allo). Control cells were left untreated in SFM. The expression of leptin protein (green immunofluorescence) was
detected with specific Abs while cell nuclei (blue fluorescence) were detected with DAPI, as described in Materials and Methods. The bar represents 10µm.
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FIGURE 2 | Allo-aca inhibits VEGF-induced chemokinesis in RF6A cells. The scratch assays were preformed as described in Materials and Methods.
Immediately after wounding, the cells were photographed (control, C) and then placed for 24 h in either SFM or incubated with 100 ng/mL VEGF in the presence or
absence of 250 nmol/L Allo-aca (Allo). The scratch areas before and after treatments were measured as described in Materials and Methods and the data are shown
in the graph. Statistically significant changes (p ≤ 0.05) are marked (SFM vs. VEGF *; VEGF vs. VEGF+Allo-aca #). The initial scratch boundaries (C) have been
marked in the picture. The bar represents 250µm.
TABLE 3 | Allo-aca inhibits VEGF-induced chemotaxis in RF/6A cells.
Treatment Migrating cells (% ± SD over SFM)
SFM 0.0
VEGF 37.6 ± 7.0*
VEGF + Allo-aca 100 20.4 ± 2.3*
VEGF + Allo-aca 250 3.4 ± 0.8
Chemotaxis induced by VEGF was measured in Boyden chamber assays as described
in Materials and Methods. VEGF was used at 100 ng/mL; Allo-aca was used at 100 and
250 nmol/L. The number of migrating cells in SFM is taken as 0%. Statistically significant
differences (p ≤ 0.05) vs. SFM are marked with asterisk.
Allo-aca Inhibits Several VEGF-Induced
Intracellular Signals in RF/6A Retinal
Endothelial Cells
To examine if VEGF activates intracellular pathways indirectly
through ObR, we stimulated RF/6A cells with 100 ng/mL VEGF
in the presence or absence of 250 nmol/L Allo-aca. Both acute (15
min) and long-term (24 h) effects on signaling molecules such as
STAT3, ERK1/2, Akt, which are common for VEGFR and ObR
were assessed (Figure 3).
At 15 min, VEGF greatly (p ≤ 0.05) increased the
phosphorylation of ERK1/2 (130 ± 16%) and Akt (181 ± 31%),
but had no significant effect on STAT3 (p ≥ 0.05). None of these
acute VEGF responses were affected by the presence of Allo-
aca (p ≥ 0.05). In contrast, at 24 h VEGF induced robust and
significant STAT3 activation (203 ± 24%) as well as maintained
increased phosphorylation of ERK1/2 (109 ± 11%) and Akt
(46 ± 5%) In the presence of Allo-aca, the long-term VEGF
effects on ERK1/2 and Akt were well suppressed (by 80 ± 12%
and 91 ± 10%, respectively), while the phosphorylation of
STAT3 was only moderately reduced (by 50 ± 10%) (p ≥ 0.05)
(Figure 3).
Allo-aca Inhibits Ocular Neovascularization
in the CNV Animal Model
Allo-aca has previously been shown to reduce leptin-
induced angiogenic effects in ocular endothelial cell models
in vitro (Scolaro et al., 2013; Parrino et al., 2014), however
the efficacy of this inhibitor in a relevant in vivo model
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FIGURE 3 | Allo-aca inhibits several VEGF-induced signaling pathways. RF/6A cells were stimulated for 15 min or 24 h with 100 ng/mL VEGF in the presence
or absence of 250 nmol/L Allo-aca (Allo); control cells were left untreated in SFM. The expression of phosphorylated (p) and total (Tot) proteins was assessed by WB
and quantified as described in Materials and Methods. The representative WB results are shown. The numbers under WB panels represent densitometry values (%) of
phosphorylated and total proteins in the blot shown, with the value in SFM taken as 100%. The average increase/decrease values from different experiments are given
under Results. Statistically significant differences vs. untreated cells are marked with * and vs. VEGF with #.
have never been tested. We used the well-recognized rat
CNV model (Shah et al., 2015) to induce robust ocular
neovascularization and probe the activity of Allo-aca to
suppress laser-induced lesions. As described before, leptin
mRNA is detectable in CNV-treated rat eyes (Scolaro et al.,
2013).
The efficacy of Allo-aca was tested in parallel with the
“standard treatment”, i.e., the VEGF Ab.
The experiment demonstrated that treatment with either
1µg anti-VEGF Ab/eye or 5µg/eye of Allo-aca resulted in
significant reduction of lesion size vs. the vehicle control group.
When compared with CNV rats injected with NaCl, anti-
VEGF intraocular injection inhibited new vessels formation
by ∼35% (p < 0.01) while injections with ObR antagonist
reduced neoangiogenesis by ∼30% (<0.05) at 22 days post
procedure. Notably, there was no significant difference in
lesion size between the group receiving anti-VEGF Ab and
Allo-aca (Figure 4). As expected, due to the multifactorial
and complex nature of the CNV (Shah et al., 2015), none
of the treatments resulted in complete reduction of the
lesions.
DISCUSSION
Several biologic drugs targeting VEGF and/or its receptor have
been approved for the use in ophthalmology. At present, VEGF
neutralizing drugs, ranibizumab (a humanized monoclonal
antibody fragment with molecular weight of 48 kDa), and
bevacizumab (a recombinant humanized monoclonal antibody
with molecular weight of 149 kDa), that were engineered to bind
with high affinity and to neutralize all biologically active isoforms
of VEGF (Ferrara et al., 2006; Scolaro et al., 2013) and aflibercept
(a fusion protein containing the second immunoglobulin domain
of VEGFR-1 and the third immunoglobulin domain of VEGFR-
2, which binds all isoforms of VEGF, VEGF-B, and placental
growth factor; Holash et al., 2002; Miller et al., 2013; Scolaro
et al., 2013) are approved for the treatment of wet AMD and
DME, and experimentally used for other eye diseases, e.g., PDR
(Willard and Herman, 2012; Scolaro et al., 2013). Most trials have
shown benefits with the use of intravitreal anti-VEGF agents for
both DME and PDR (Cheung et al., 2010; Scolaro et al., 2013).
However, adverse effects (systemic and ocular) and development
of resistance to the treatment have been noted with long-term
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FIGURE 4 | Allo-aca inhibits laser-induced choroidal neovascularization in vivo. Choroidal neovascularization (CNV) was induced by bilateral laser treatment
as described in Materials and Methods. Three days post-injury, the animals received bilateral intravitreal injections of NaCl, an anti-VEGF antibody 5µg/eye or Allo-aca
5µg/eye. Three weeks post-laser treatment, fluorescein angiography was performed and lesion size area was determined with image analysis software. The
representative angiography results (fundus images of 3 lesions) in NaCl and Allo-aca treated eyes are shown. The graphs show the average area of lesion size area at
the experimental end point. Statistical significance calculated with Student’s t-test. *p ≤ 0.05; **p ≤ 0.01.
use, thus targeting pro-angiogenic factors other than VEGF could
be prove to be an effective alternative or complementary therapy
for pathological neovascularization in the eye (Praidou et al.,
2010; Tang and Kern, 2011; Truong et al., 2011; Stewart, 2012;
Willard and Herman, 2012)
In addition to VEGF, many other molecular players including
pro-angiogenic and pro-inflammatory cytokines, anti-angiogenic
factors, integrins and matrix proteinases have been implicated
in ocular pathologies (Praidou et al., 2010; Truong et al.,
2011; Wang et al., 2012). Recent data, including that from
our laboratory, suggest that leptin, a cytokine implicated in
neovascularization, proliferation and inflammation can induce
growth and angiogenic differentiation of ocular endothelial cells
in vitro (Cao et al., 2001; Suganami et al., 2004; Sun et al., 2011;
Scolaro et al., 2013) and might be implicated in DR (Gariano
et al., 2000; Parrino et al., 2014). Furthermore, targeting ObR
has been shown to inhibit most of biological effects of leptin
in ocular disease models (Scolaro et al., 2013; Parrino et al.,
2014). This new direction in evaluating leptin a target in ocular
neovascularization needs further assessment in light of reports
showing differential (andmodel specific) leptin influence on such
components of vasculature as vascular smooth muscle cells (Oda
et al., 2001; Bohlen et al., 2007; Rodriguez et al., 2010).
Our previous preliminary observations suggested that
simultaneous inhibition of leptin and VEGF pathways was
more efficacious in suppressing angiogenesis than individual
treatments in HUVEC cells (Ferla et al., 2011). The existence of
leptin/VEGF crosstalk has been noted in different experimental
models (Sierra-Honigmann et al., 1998; Suganami et al., 2004;
Gonzalez-Perez et al., 2010; Ferla et al., 2011; Garonna et al.,
2011). However, the functional links between leptin and VEGF
have not been sufficiently explored in the context of eye disease
and relevant therapeutic interventions. While leptin has been
shown to stimulate VEGF expression and potentiate ocular
neovascularization, the impact of VEGF on leptin signaling has
never been tested.
Here, we demonstrate for the first time that VEGF increases
leptin mRNA and protein expression in retinal and corneal
endothelial cells. These effects are accompanied by increased
cell growth and cell and are abolished in the presence of
ObR antagonist, Allo-aca. In addition, VEGF promotes cell
chemotaxis and chemokinesis in retinal endothelial cells, which
at least in part is restricted by Allo-aca. Likewise, many long-
term, but not acute, intracellular signaling effects of VEGF
are blocked in the presence of Allo-aca. These VEGF-induced
intracellular signals (ERK1/2, Akt) are common for ObR
and VEGFR pathways. All these observations suggest that
VEGF indirectly activates leptin pathways by upregulating
leptin expression, thus, potentiating leptin signaling.
Increased leptin concentration, in turn, likely can activate
its own expression as well as upregulate VEGF expression,
thereby greatly enhancing pro-angiogenic environment in
the eye.
We previously demonstrated that inhibition of angiogenesis
in vitro by combined ObR and VEGF inhibitors is more
efficacious than individual treatments (Ferla et al., 2011). Our
present study shows that the efficacy of ObR antagonist Allo-aca
in restricting experimental neovascularization in animal models
is similar to that achieved with compounds targeting VEGF. This
suggests that development of therapeutic approaches interfering
simultaneously or sequentially with both pathways could be
clinically beneficial.
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